Open Access
Review
| Issue |
Cah. Myol.
Number 19, Juin 2019
|
|
|---|---|---|
| Page(s) | 25 - 27 | |
| Section | Mise au point / Focus | |
| DOI | https://doi.org/10.1051/myolog/201919007 | |
| Published online | 5 juillet 2019 | |
- Hayes TG, Pharmacologic treatment of male breast cancer. Expert Opin Pharmacother. 2009 ; 10 : 2499–510. [CrossRef] [PubMed] [Google Scholar]
- Peddi PF, Hormone receptor positive breast cancer: state of the art. Curr Opin Obstet Gynecol. 2018 ; 30 : 51–4. [CrossRef] [PubMed] [Google Scholar]
- Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M, Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013 ; 1 : 749–57. [CrossRef] [PubMed] [Google Scholar]
- Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC, Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006 ; 56 : 301–5. [CrossRef] [PubMed] [Google Scholar]
- Kreher NC, Eugster EA, Shankar RR, The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics. 2005 ; 116 : 1513–5. [CrossRef] [PubMed] [Google Scholar]
- Derman O, Kanbur N, Kilic I, Kutluk T, Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia. J Pediatr Endocrinol Metab. 2008 ; 21 : 449–54. [CrossRef] [PubMed] [Google Scholar]
- Dorchies OM, Reutenauer-Patte J, Dahmane E, et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol. 2013 ; 182 : 485–504. [CrossRef] [PubMed] [Google Scholar]
- Gayi E, Neff LA, Ismail HM, Ruegg UT, Scapozza L, Dorchies OM, Repurposing the selective oestrogen receptor modulator tamoxifen for the treatment of Duchenne muscular dystrophy. Chimia (Aarau). 2018 ; 72 : 238–40. [CrossRef] [PubMed] [Google Scholar]
- Cowling BS, Chevremont T, Prokic I, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest. 2014 ; 124 : 1350–63. [CrossRef] [PubMed] [Google Scholar]
- Gayi E, Neff LA, Massana Muñoz X, et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018 ; 9 : 4848. [CrossRef] [PubMed] [Google Scholar]
- Cowling BS, Prokic I, Tasfaout H, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest. 2017 ; 127 : 4477–87. [CrossRef] [PubMed] [Google Scholar]
- Demonbreun AR, McNally EM, Dynamin 2 the rescue for centronuclear myopathy. J Clin Invest. 2014 ; 124 : 976–8. [CrossRef] [PubMed] [Google Scholar]
- Böhm J, Vasli N, Maurer M, et al., Altered splicing of the BIN1 muscle-specific exon in humans and dogs with highly progressive centronuclear myopathy. PLoS Genet. 2013 ; 9 : e1003430. [PubMed] [Google Scholar]
- Ismail HM, Dorchies OM, Scapozza L, The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. Expert Opin Orphan Drugs. 2018 ; 6 : 259–71. [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.